Europe Next-generation Sequencing Market Size, Growth, Share & Trends Analysis
Europe Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture)-Forecast to 2030
OVERVIEW
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The Europe Next-generation Sequencing Market, valued at US$4.11 billion in 2024, stood at US$4.42 billion in 2025 and is projected to advance at a resilient CAGR of 15.0% from 2025 to 2030, culminating in a forecasted valuation of US$8.88 billion by the end of the period.The Europe next-generation sequencing market is expanding on the back of accelerating use of sequencing across oncology, rare disease diagnostics, and broader precision medicine programs, supported by robust public and private research funding. Growth is further underpinned by rising cancer and genetic disease burdens across the region, national and EU-level genomic initiatives, and ongoing technological advances.
KEY TAKEAWAYS
-
By RegionThe German next-generation sequencing market accounted for a 23.5% revenue share in 2024.
-
By OfferingsBy offering, the services segment is expected to register the highest growth during the forecast period.
-
Product Market, By TypeIn the product market, by type, the consumables segment is expected to dominate the market.
-
Services Market, By TypeIn the services market, by type, the sequencing market segment is expected to dominate the market.
-
Products Market, By End userIn the product market, by end user, the pharmaceutical & biotechnology companies segment is projected to grow at the fastest rate from 2025 to 2030.
-
Services Market, By End userIn the services market, by end user, the academic & research institutes segment is projected to grow at the highest rate from 2025 to 2030.
-
By ApplicationBy application, the diagnostics segment is projected to grow at the fastest rate from 2025 to 2030.
-
Competitive LandscapeIllumina, Inc., Thermo Fisher Scientific, and F. Hoffmann-La Roche Ltd. were identified as key players in the Europe next-generation sequencing market, given their strong market share and extensive product footprint.
-
Competitive LandscapeNucleus Biotech GmbH, PCR Biosystems, and GeneFirst Limited, among others, have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders
The European next-generation sequencing market is experiencing robust growth, driven by rising demand for high-throughput genomic technologies that support accurate disease diagnosis, targeted therapy selection, and advanced translational research throughout the region. Increasing adoption of NGS in oncology, rare disease, and reproductive health testing, as well as in liquid biopsy applications, together with strong government-backed genomic initiatives, expanding use in academic and reference laboratories, and growing engagement from biopharmaceutical companies, is further strengthening market momentum despite persisting variability in national reimbursement frameworks.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The impact on stakeholders’ businesses of next-generation sequencing market in Europe is shaped by shifting healthcare priorities, rapid technological progress, and growing patient demand for personalized, data-driven care. Hospitals, clinical laboratories, academic and government research institutes, and pharmaceutical and biotechnology companies are the primary adopters of NGS solutions, with use cases spanning oncology, rare disease diagnostics, reproductive health, liquid biopsy, and drug discovery.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Integration of genomic medicine into national health systems
-
Policy focus on precision oncology and rare diseases
Level
-
Uneven reimbursement and infrastructure across countries
Level
-
Growth of multi-omics, data analytics, and biopharma collaborations
Level
-
Limited specialized workforce and uneven access to genomic services
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Integration of genomic medicine into national health systems
Several European countries are embedding NGS into routine care through national genomic medicine initiatives. The UK’s 100,000 Genomes Project and Genomics England program, France’s Genomic Medicine 2025 plan, and similar efforts in other EU states are establishing sequencing centres, clinical networks, and data platforms focused on cancer and rare diseases. These programs create stable, government-backed demand for NGS instruments and consumables and accelerate clinical guideline adoption. As more indications are added, volumes from public hospitals and pathology labs continue to grow across Europe.
Restraint: Uneven reimbursement and infrastructure across countries
Reimbursement pathways for NGS vary widely across European countries and even within regions of the same country. Surveys of laboratories show that while some tests receive government reimbursement, others lack codes or face complex prior-authorization processes, leaving some patients without funded access. Infrastructure for high-quality NGS, including validated assays, quality systems, and biobanking, also differs markedly between Western Europe and parts of Central and Eastern Europe. This heterogeneity limits the scalability of pan-European testing strategies and complicates market entry for new assays and platforms.
Opportunity: Growth of multi-omics, data analytics, and biopharma collaborations
European biopharma companies and academic consortia are expanding the use of NGS in early-stage research, biomarker discovery, and adaptive clinical trials. There is growing interest in integrating NGS with other omics and advanced analytics to elucidate disease mechanisms and stratify patients more precisely. Reports on the regional genomics and data-analysis markets highlight strong investment in bioinformatics tools and cross-border research collaborations. This creates opportunities for NGS providers to offer integrated solutions—sequencing, high-performance computing, AI-driven interpretation, and secure data platforms—tailored to the needs of European R&D and translational medicine.
Challenge: Limited specialized workforce and uneven access to genomic service
Experts across Europe point to shortages of clinical geneticists, molecular pathologists, bioinformaticians, and genomics-literate clinicians as a key obstacle to broader NGS implementation. Studies note a lack of staff training, expertise, and organizational readiness as frequent reasons hospitals underuse available sequencing technologies. Combined with infrastructure gaps between well-funded centres and smaller or rural hospitals, these factors lead to inequities in who can benefit from NGS-based diagnostics. Addressing workforce development, education, and regional capacity-building will be essential to ensure that the benefits of NGS are shared more evenly across European populations.
EUROPE NEXT-GENERATION SEQUENCING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
The Regina Maria Genetic Laboratory (Romania) adopted Illumina NGS solutions in house | Optimized laboratory operations | Efficient prioritisation of work | Improved turnaround times |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The Europe next-generation sequencing market ecosystem comprises instrument and reagent suppliers, including Illumina, Thermo Fisher Scientific, Roche, Qiagen, Oxford Nanopore Technologies, and several regional players, along with a growing base of bioinformatics and software providers, clinical and research laboratories, and healthcare end users. Technology vendors deliver sequencing platforms, consumables, and data-analysis solutions that support high-throughput genomic testing, while hospitals, diagnostic laboratories, academic institutes, and biopharmaceutical companies integrate these tools into clinical diagnostics, population and translational research, and drug development programs across Europe.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Europe NGS Market, By Offerings
In 2024, products held the biggest share of the Europe next-generation sequencing market. Labs continue to buy sequencing instruments, consumables, reagents, and library preparation kits on a recurring basis. These products support high-throughput workflows, including oncology panels, whole-exome sequencing (WES), whole-genome sequencing (WGS), and liquid biopsy. Upgradation in chemistry, automation, and workflow efficiency continue to enhance their role, even as services and data analysis grow quickly.
Europe NGS Products Market, By Type
Within products, consumables were the largest segment in 2024 due to the repeated use of reagents, kits, and library prep components in routine sequencing. Demand is steady across hospitals, reference labs, and research centres. High testing volumes in oncology, reproductive health, infectious diseases, and drug discovery keep spending levels strong. Also, innovation in sample preparation, target enrichment, and sequencing chemistries supports continued consumables growth.
Europe NGS Services Market, By Type
In services, sequencing services are leading the Europe next-generation sequencing market in 2024 and are expected to remain the leading service type. Demand is strong for WGS, WES, targeted panels, RNA sequencing, and related workflows across research, clinical, and biopharma users. Lower sequencing costs are aiding adoption. Growth in oncology and rare disease testing is also giving volume growth. Additionally, national genomics programs and population studies are driving the need for scalable capacity, leading to repeat projects and longer-term provider contracts.
Europe NGS Market, By Application
By application, drug discovery & development was the largest segment in 2024 and is likely to stay the leading application over the forecast period. NGS is important for target identification, biomarker discovery, and translational research. Pharmaceutical and biotech companies are growing these programs through academic collaborations.
REGION
Germany to be the fastest-growing country in the Europe NGS market during the forecast period
The next-generation sequencing market in Germany is poised for significant growth in the coming years. This growth is driven by a national focus on incorporating genomics into standard everyday medical care. Demand is also being boosted by biopharma companies using NGS in research and clinical trials to identify specific biomarkers. There is also a growing focus on using molecular diagnostics for personalized cancer treatment (precision oncology) and for diagnosing infectious diseases. Companies in this space are investing heavily in new technology, automating processes, utilizing AI for data analysis, and developing secure, cloud-based data platforms that comply with Germany's stringent data privacy regulations. These advancements are making it easier to scale high-volume, decentralized sequencing operations across the nation.
EUROPE NEXT-GENERATION SEQUENCING MARKET: COMPANY EVALUATION MATRIX
In the Europe next-generation sequencing market matrix, Illumina (Star) holds a leading position, backed by a large installed base and a broad portfolio of high-throughput, benchtop, and clinical sequencers, complemented by widely adopted reagents, library preparation kits, and data-analysis solutions across research institutes, clinical laboratories, and biopharmaceutical organizations. Oxford Nanopore Technologies (Emerging Leader) is rapidly gaining visibility in Europe through its long-read, real-time sequencing platforms, increasingly used in clinical research, rare disease and cancer genomics, and decentralized sequencing applications.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Illumina, Inc. (US)
- Thermo Fisher Scientific, Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Eurofins Scientific (Luxembourg)
- Oxford Nanopore Technologies plc (UK)
- QIAGEN (Germany)
- Agilent Technologies, Inc. (US)
- Danaher Corporation (US)
- Revvity (US)
- Bio-Rad Laboratories, Inc. (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2024 (Value) | USD 4.11 Billion |
| Market Forecast in 2030 (Value) | USD 8.88 Billion |
| Growth Rate | CAGR of 15.0% from 2025-2030 |
| Years Considered | 2023-2030 |
| Base Year | 2024 |
| Forecast Period | 2025-2030 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Countries Covered | Germany, UK, France, Italy, Spain, Rest of Europe |
WHAT IS IN IT FOR YOU: EUROPE NEXT-GENERATION SEQUENCING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Global NGS platform & reagents manufacturer |
|
|
| Leading European university hospital / genomics center |
|
|
RECENT DEVELOPMENTS
- July 2024 : F. Hoffmann-La Roche Ltd. (Switzerland) acquired Point of Care Technology from LumiraDx (UK) to support its multi-assay point of care platform.
- May 2024 : Oxford Nanopore Technologies collaborated with Twist Bioscience to launch a new Pharmacogenomics (PGx) Beta Programme. This long-read PGx solution, available for research use, is designed to provide unambiguous genetic results in a single end-to-end workflow from sample to PGx star allele call.
- October 2022 : Illumina, Inc. (US) and GenoScreen (France) partnered to expand access to genomic testing for multidrug-resistant tuberculosis in countries most impacted by tuberculosis.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study on the Europe Next-generation Sequencing Market employed secondary sources, directories, and databases to gather pertinent information. To gather and validate important qualitative and quantitative data and evaluate market growth prospects, in-depth interviews were conducted with many primary respondents including key industry participants, subject-matter experts (SMEs), C-level executives from key market players, and industry consultants. After estimating theEurope Next-generation Sequencing Market using several research strategies, the size of the final market was obtained by triangulating data from primary research.
Secondary Research
The secondary sources referred to for this research study include publications from government sources. These include the Centers for Disease Control and Prevention (CDC), the US Food and Drug Administration (FDA), the World Health Organization (WHO), the American Cancer Society (ACS), the National Center for Biotechnology Information (NCBI), the National Institutes of Health (NIH), National Human Genome Research Institute (NHGRI), International Agency for Research on Cancer (IARC), National Institute for Infectious Diseases (IRCCS), Association for Clinical Genomic Science (ACGS), American Society of Human Genetics (ASHG), European Society of Human Genetics (ESHG), Asia Pacific Society of Human Genetics (APSHG), Nature Reviews Genetics, Nature Methods, Biotechnology and Biological Sciences Research Council (BBSRC), Organisation for Economic Co-operation and Development (OECD), Genome Research, National Cancer Institute (NCI), European Medicines Agency (EMA), Population Health Research Institute (PHRI), PubMed, World Bank, and the World Health Organization (WHO), among others. Secondary sources also included corporate & regulatory filings, such as annual reports, SEC filings, investor presentations, and financial statements; business magazines & research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the globalEurope Next-generation Sequencing Market, which was validated through primary research.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global Europe Next-generation Sequencing Market scenario through secondary research. Several primary interviews were conducted with market experts from the supply side, such as C-level and D-level executives, operational managers, marketing & sales managers of key manufacturers, distributors, and channel partners of companies providing NGS; experts from the demand side, such as personnel from academic & research institutes, hospitals, clinics and diagnostic labs, pharmaceutical & biopharmaceutical industries, CROs, and other end users. These interviews were conducted across six major regions, including North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. Approximately 70% and 30% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the Europe Next-generation Sequencing Market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
NGS refers to non-Sanger-based, high-throughput DNA sequencing technologies. DNA strands can be sequenced simultaneously, yielding substantially more throughput and minimizing the need for fragment-cloning methods often used in the Sanger sequencing of genomes. NGS is fundamentally based on sequencing by synthesis (SBS), ion semiconductor sequencing, single-molecule real-time (SMRT) sequencing, and nanopore sequencing.
Stakeholders
- NGS instrument manufacturers, vendors, and distributors
- NGS service providers
- NGS bioinformatics/data analysis companies
- Research laboratories and academic institutes
- Venture capitalists and other government funding organizations
- Research and consulting firms
- Healthcare institutions (hospitals and diagnostic clinics)
- Pharmaceutical and biotechnology companies
- Academic and government research institutes
- Life science companies
Report Objectives
- To define, describe, and forecast the Europe Next-generation Sequencing Market based on offerings, product type, platform technology, product workflow, product end user, service type, service workflow, service end user, application, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the overallEurope Next-generation Sequencing Market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global Europe Next-generation Sequencing Market and comprehensively analyze their platforms, reagents, kits, consumables, and services portfolios, market positions, and core competencies
- To track and analyze competitive developments such as product & service launches, expansions, agreements, and collaborations in the Europe Next-generation Sequencing Market
- To benchmark players within the Europe Next-generation Sequencing Market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This ReportPersonalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Europe Next-generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free Customisation
Growth opportunities and latent adjacency in Europe Next-generation Sequencing Market